Fushilai (Shandong) Pharmaceutical Co., Ltd. annpunced that it will raise CNY 200 million in an equity funding on December 18, 2023. The transaction will include participation from returning investor, Suzhou Fushilai Pharmaceutical Co., Ltd. The transaction has been approved at the 10th session of the company?s 4th directorate and the 9th session of the company?s 4th supervisory board.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.87 CNY | -2.83% | +38.13% | +20.42% |
1st Jan change | Capi. | |
---|---|---|
+20.42% | 507M | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- 301258 Stock
- News Suzhou Fushilai Pharmaceutical Co., Ltd.
- Fushilai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Suzhou Fushilai Pharmaceutical Co., Ltd.